50623-73-9

Usage

Uses

Used in Organic Synthesis:
(+)-1,4-Di-O-tosyl-D-threitol is used as a chiral resolving agent for the separation of racemic mixtures and the determination of enantiomeric purity. Its ability to form diastereomeric salts with different enantiomers makes it a valuable tool in this field.
Used in Preparation of Chiral Ligands and Catalysts:
(+)-1,4-Di-O-tosyl-D-threitol is also utilized in the preparation of chiral ligands and catalysts for asymmetric synthesis. The tosyl group in the compound serves as a protecting group for the hydroxyl groups of threitol, allowing for selective reactions at specific positions.

InChI:InChI=1/C18H22O8S2/c1-13-3-7-15(8-4-13)27(21,22)25-11-17(19)18(20)12-26-28(23,24)16-9-5-14(2)6-10-16/h3-10,17-20H,11-12H2,1-2H3/t17-,18-/m1/s1

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 37002-45-2 (4S,5S)-2,2-dimethyl-4,5-bis(p-toluenesulfonyloxymethyl)-1,3-dioxolan 
• 98-59-9 p-toluenesulfonyl chloride 
• 51064-65-4 1,4-di-o-tosyl-2,3-isopropylidene-D-threitol 

Downstream Products

• 231607-42-4 C₁₈H₂₀O₉S₃ 
• 231607-41-3 C₁₈H₂₁N₃O₇S₂ 
• 201402-92-8 C₁₈H₂₀O₁₀S₃ 
• 201402-95-1 Acetic acid 3-{(S)-4-[(S)-1-hydroxy-2-(toluene-4-sulfonyloxy)-ethyl]-4,5-dihydro-oxazol-2-yl}-2-methyl-phenyl ester 
• 201402-96-2 C₂₆H₂₅NO₉S₂ 
• 163439-82-5 (3R,4R)-1-benzyl-3,4-pyrrolidinediol 

Relevant academic research and scientific papers

Optimization of an electrolyte system for the simultaneous separation of nelfinavir mesylate and two impurities by micellar electrokinetic chromatography

A methodology for the simultaneous determination of nelfinavir mesylate and the impurities 3-hydroxy-2-methylbenzoic acid and (2R,3R)-4-((3S,4aS,8aS)-3-(tert-butylcarbamoyl) octahydroisoquinolin-2(1H)-yl)-3-hydroxy-1-(phenylthio)butan-2-aminium benzoate by micellar electrokinetic chromatography, with an analysis time of 25 min, was proposed. An electrolyte composed of sodium tetraborate buffer (pH 9.24; 25 mmol L-1), sodium dodecyl sulphate (9 mmol L-1) and methanol (10percent, v/v) was optimized using a mixed-level factorial design, with direct detection at 200 nm. After evaluating some figures of merit, such as selectivity, linearity, precision, limit of detection, limit of quantification, accuracy and robustness (using Youden's test), the method was successfully applied to the analysis of nelfinavir mesylate and its impurities in a pharmaceutical formulation. The optimized methodology is demonstrated to be useful in the determination of these analytes in a synthesis monitoring process, in raw materials and in pharmaceutical formulations, while offering low solvent consumption, requiring a small sample and using non-specific columns as advantages.

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.

ACYCLIC 1,4-DIAMINES AND USES THEREOF

This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain acyclic diamines, which are agonists of TRPV4 channel receptors.

2-IMINOPYRROLIDINE DERIVATES

A 2-iminopyrrolidine derivative represented by the formula: {wherein ring B represents a benzene ring, pyridine ring, etc.; R101 - R103 represent hydrogen, halogen, C1-6 alkyl, etc.; R5 represents hydrogen, C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, etc.; R6 represents hydrogen, C1-6 alkyl, C1-6 alkyloxycarbonyl, etc.; Y1 represents a single bond, -CH2-, etc.; Y2 represents a single bond, -CO-, etc.; and Ar represents hydrogen, a group represented by the formula: [wherein R10-R14 represent hydrogen, C1-6 alkyl, hydroxyl, C1-6 alkoxy, etc.; and R11 and R12 or R12 and R13 may bond together to form a 5- to 8-membered heterocyclic ring], etc.}, or a salt thereof.

A synthesis of the HIV-protease inhibitor nelfinavir from D-tartaric acid

This letter describes a new synthesis of the HIV-protease inhibitor nelfinavir. The synthesis features a selective opening of a D-tartaric acid-derived cyclic sulfate with nitrogen nucleophiles.

Radical cyclization of β-alkoxyacrylates: A formal synthesis of (-)-kumausallene

Radical cyclization reaction of a bis(β-alkoxyacrylate) intermediate prepared from (-)-diethyl D-tartrate proceeded stereoselectively to give a 2,6-dioxabicyclo[3.3.0]octane product, which was converted into a known intermediate in the synthesis of kumausallene.